Agenus

Founder‑CEO Garo Armen remains at the helm with meaningful but not controlling ownership (about 4.3% as of April 22, 2026). Clinical leadership under CMO Steven O’Day has advanced BOT+BAL across multiple tumor types and achieved FDA Fast Track designation in MSS CRC.

Governance and incentives show ongoing equity‑based compensation and a 2026 option exchange proposal to retain talent. However, long reliance on capital markets, frequent program pivots, and the need for large Phase 3 execution reduce our confidence score.

Notably, an SEC investigation concluded with no enforcement recommendation and a 2024 securities class action was dismissed at the district court level, though an appeal is pending.